Combining all-trans retinoic acid (ATRA) with arsenic trioxide (ATO) and idarubicin significantly improved event-free survival (EFS) compared with the standard treatment of ATRA and ...
All-trans retinoic acid and arsenic trioxide (ATRA-ATO) combination therapy demonstrates superior event-free survival and lower molecular relapse rates compared to standard ATRA plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results